NMTRYPI
New Medicines for Trypanosomatidic Infections
| Coordinatore | UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Organization address
address: VIA UNIVERSITA 4 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 7˙609˙868 € |
| EC contributo | 5˙901˙411 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-02-01 - 2017-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Organization address
address: VIA UNIVERSITA 4 contact info |
IT (MODENA) | coordinator | 746˙284.00 |
| 2 |
HITS GGMBH
Organization address
address: SCHLOSS WOLFSBRUNNENWEG 35 contact info |
DE (HEIDELBERG) | participant | 681˙809.00 |
| 3 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 615˙968.80 |
| 4 |
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Organization address
address: BERNHARD NOCHT STRASSE 74 contact info |
DE (HAMBURG) | participant | 517˙965.00 |
| 5 |
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC
Organization address
address: RUA DO CAMPO ALEGRE 823 contact info |
PT (PORTO) | participant | 412˙718.80 |
| 6 |
ETHNIKO IDRYMA EREVNON
Organization address
address: Vassileos Constantinou Avenue 48 contact info |
EL (ATHENS) | participant | 409˙134.50 |
| 7 |
UNIVERSIDAD COMPLUTENSE DE MADRID
Organization address
address: AVENIDA DE SENECA 2 contact info |
ES (MADRID) | participant | 394˙700.80 |
| 8 |
Hypha Discovery Limited
Organization address
address: "Briar Cottages, Bakers Lane 1" contact info |
UK (Maidenhead) | participant | 374˙733.84 |
| 9 |
TYDOCK PHARMA S.r.l
Organization address
address: Strada Gherbella 294/b contact info |
IT (Modena) | participant | 370˙570.00 |
| 10 |
CENTRO NACIONAL DE PESQUISA EM ENERGIA E MATERIAS ASSOCIACAO PRIVADA
Organization address
address: RUA GIUSEPPE MAXIMO SCOLFARO 10000 contact info |
BR (CAMPINAS) | participant | 365˙965.20 |
| 11 |
Interface Europe
Organization address
address: Rue du Trone 12 contact info |
BE (Bruxelles) | participant | 354˙680.00 |
| 12 |
UNIVERSITA' DEGLI STUDI DI SIENA
Organization address
address: VIA BANCHI DI SOTTO 55 contact info |
IT (SIENA) | participant | 340˙740.00 |
| 13 |
NATIONAL CENTER FOR RESEARCH
Organization address
address: El-Mak Nimir Street contact info |
SD (Khartoum) | participant | 228˙860.00 |
| 14 |
EUROPEAN SCREENINGPORT GMBH
Organization address
address: SCHNACKENBURGALLEE 114 contact info |
DE (HAMBURG) | participant | 87˙281.18 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drugs, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and Brazil). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners’expertise and the integrated platform that will provide: - at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones, - early phase biomarkers for efficacy prediction (overall improved efficacy and safety)'